Blockage of the PD1 axis by an anti-PD-1/PD-L1/PD-L2 antibody prevents the inhibition of the immune response, leading to enhanced tumor cell killing by increased T-cell activation and proliferation [33]. This evidence concerns the gene PDCD1 and neoplasm.